Poolbeg Pharma (POLB) , a clinical-stage biopharma company focused on infectious diseases, announced it will present data related to its flagship POLB 001 anti-inflammatory candidate at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held 9-12 December 2023 in San Diego.
Poolbeg's presentation will focus on POLB 001's potential to treat hyperinflammation associated with cytokine release syndrome (CRS) that affects patients receiving CAR T-cell cancer therapies. CRS is an often encountered side effect of such immunotherapies that causes potentially life-threatening hyperinflammation. CRS is also associated with severe influenza.
Specifically, Poolbeg will provide insight into results obtained from the POLB 001 LPS human challenge trial, highlighting its potential use in the treatment of CRS.
View from Vox
The acceptance of Poolbeg's abstract on POLB 001 at ASH represents further validation of the candidate's potential in addressing CRS in oncology. The ASH Annual Meeting and Exposition is recognised as the world's premier conference focusing on hematological malignancies (blood cancers), bringing together 25,000 industry and academic attendees each year to share the latest advances in clinical care.
CRS is highly prevalent among patients receiving immunotherapy for hematological malignancies. Mild to moderate cases of CRS require hospitalisation and can impact the ability to deliver the cancer immunotherapies while severe cases can become life-threatening and may require intensive care, and in rare cases cause mortality.
An effective drug for CRS has the potential to make cancer immunotherapies more tolerable and widely accessible, and enable patients to best benefit from their treatment. Positive results from the POLB 001 LPS challenge trial highlighted that oral treatment of POLB 001 holds substantial promise in tackling the issue of hyperinflammation associated with CRS.
Follow News & Updates from Poolbeg Pharma: